These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9474479)

  • 1. Anti-gram-positive agents. What we have and what we would like.
    Grüneberg RN
    Drugs; 1997; 54 Suppl 6():29-38. PubMed ID: 9474479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of teicoplanin in the treatment of serious neonatal infections.
    Fanos V; Kacet N; Mosconi G
    Eur J Pediatr; 1997 Jun; 156(6):423-7. PubMed ID: 9208233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teicoplanin in the treatment of serious infection.
    Schaison G; Graninger W; Bouza E
    J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glycopeptide resistant enterococci. Occurrence, distribution, resistance transmission, significance].
    Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):293-300. PubMed ID: 9265387
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacokinetic characteristics and antimicrobial spectrum of teicoplanin].
    Paganini H; Marin M
    Medicina (B Aires); 2002; 62 Suppl 2():52-5. PubMed ID: 12481490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of teicoplanin against gram-positive cocci.
    Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
    Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Teicoplanin. New treatment potentials for gram-positive infections in the hospital].
    Iakovlev SV
    Antibiot Khimioter; 1999; 44(2):3-7. PubMed ID: 10202550
    [No Abstract]   [Full Text] [Related]  

  • 18. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia.
    Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M
    J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.